最新ニュース Neogen (NASDAQ:NEOG) 株価情報

Neogen

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries.

News

Movers

ACLS

AGIO

HALO

IRTC

LBTYB

LEGN

NEOG

NUVL

NVAX

NVDA

SMAR

TWST

VRNT

これらの中型株は直近1週間で最も好調のパフォーマンスを示しました。あなたのポートフォリオには入っていますか？

直近1週間高パフォーマンスを示したのは、中型株

Neogen Corp

NEOGAMES SA SHS USD

NeoGenomics Inc

General

NeoGenomics shares are trading higher following strong FY25 guidance.

Neogen Files For Non-Timely 10-Q With U.S. SEC; Expects To Record An Impairment Charge Of $461.4M In Q2; Expects Form 10-Q Will Report Net Loss Of $456.3M For Qtr Ended Nov 30, 2024

WIIM

Neogen shares are trading lower after the company issued FY25 revenue guidance below estimates.

Neogen Corporation Sees Fy25 Revenue Of $905M-$925M Vs. $934.88M Estimate (Prior View: $925M-$955M)

Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.10 by 10 percent. The company reported quarterly sales of $231.258 million which beat the analyst consensus estimate of $227.159 million by 1.80 percent. This is a 0.71 percent increase over sales of $229.629 million the same period last year.

Earnings

Earnings Beats

Neogen Q2 2025 Adj. EPS $0.11 Beats $0.10 Estimate, Sales $231.258M Beat $227.159M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) is likely to report quarterly earnings at $3.32 per share on revenue of $2.54 billion. 
• E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $161.00 million. 
• Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $226.65 million. 
• Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is expected to report quarterly earnings at $0.46 per share on revenue of $37.20 billion. 
• Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) is projected to report earnings for its second quarter. 
• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $3.07 per share on revenue of $15.30 billion. 
• Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) is projected to report quarterly earnings at $1.74 per share on revenue of $14.64 billion. 
<h3>Companies Reporting After The Bell</h3>
• WD-40 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) is projected to report quarterly earnings at $1.31 per share on revenue of $147.44 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ETWO

TLRY

WDFC

Earnings Scheduled For January 10, 2025

Guggenheim analyst Subbu Nambi initiates coverage on Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with a Buy rating and announces Price Target of $15.

Price Target

Initiation

Analyst Ratings

Guggenheim Initiates Coverage On Neogen with Buy Rating, Announces Price Target of $15

Neogen shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results. Also, the company announced its COO will retire in early 2025.

Neogen&rsquo;s operations organization will transition to report to David H. Naemura, Chief Financial Officer. Mr. Jones will work closely with Mr. Naemura on this transition. Mr. Jones also will continue to lead the commercial organization until the Chief Commercial Officer role is filled and will oversee the transition of this function to his successor.

Management

Neogen COO Douglas E. Jones Intends To Retire In Early 2025 - Filing

Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) affirms FY2025 sales outlook from $925.00 million-955.00 million to $925.00 million-955.00 million.

Guidance

Neogen Affirms FY2025 Sales Guidance to $925.00M-955.00M (Est. 934.885M)

Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.09 by 22.22 percent. The company reported quarterly sales of $217.000 million which beat the analyst consensus estimate of $215.056 million by 0.90 percent. This is a 5.23 percent decrease over sales of $228.987 million the same period last year.

Earnings Misses

Neogen Q1 2025 Adj. EPS $0.07 Misses $0.09 Estimate, Sales $217.000M Beat $215.056M Estimate

Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) is set to give its latest quarterly earnings report on Thursday, 2024-10-10. Here's what investors need to know before the announcement.
Analysts estimate that Neogen will report an earnings per share (EPS) of $0.08. 
Investors in Neogen are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.01, leading to a 3.13% drop in the share price the following trading session.
Here's a look at Neogen's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.11</td>
<td>0.14</td>
<td>0.14</td>
<td>0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.10</td>
<td>0.12</td>
<td>0.11</td>
<td>0.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-4.0%</td>
<td>3.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1728482425_0.png" alt="eps graph" />
<h3>Tracking Neogen's Stock Performance</h3>
Shares of Neogen were trading at $14.69 as of October 08. Over the last 52-week period, shares are down 2.27%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Opinions on Neogen</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Neogen.
With 1 analyst ratings, Neogen has a consensus rating of Neutral. The average one-year price target is $17.5, indicating a potential 19.13% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Haemonetics, UFP Techs and ICU Medical, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Haemonetics is maintaining an Outperform status according to analysts, with an average 1-year price target of $105.57, indicating a potential 618.65% upside.</li>
<li>Analysts currently favor an Buy trajectory for UFP Techs, with an average 1-year price target of $392.0, suggesting a potential 2568.48% upside.</li>
<li>The consensus among analysts is an Outperform trajectory for ICU Medical, with an average 1-year price target of $165.0, indicating a potential 1023.21% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Haemonetics, UFP Techs and ICU Medical are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neogen</td>
<td>Neutral</td>
<td>-2.07%</td>
<td>$113.48M</td>
<td>-0.17%</td>
</tr>
<tr>
<td>Haemonetics</td>
<td>Outperform</td>
<td>7.98%</td>
<td>$174.92M</td>
<td>4.11%</td>
</tr>
<tr>
<td>UFP Techs</td>
<td>Buy</td>
<td>10.14%</td>
<td>$33.03M</td>
<td>4.48%</td>
</tr>
<tr>
<td>ICU Medical</td>
<td>Outperform</td>
<td>8.58%</td>
<td>$207.43M</td>
<td>-1.04%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Neogen ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. For Return on Equity, Neogen is at the bottom.
<h3>Get to Know Neogen Better</h3>
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries.
<h3>Financial Insights: Neogen</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Neogen faced challenges, resulting in a decline of approximately -2.07% in revenue growth as of 31 May, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Neogen's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -2.29%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.17%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Neogen's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.12%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.28.
<a href="https://www.benzinga.com/quote/NEOG/earnings">To track all earnings releases for Neogen visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Neogen's Earnings Potential

Neogen&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neog#NASDAQ">NEOG</a>) vast international trade is impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell).
Neogen&#39;s international business continues to be affected by currency movements.
The current macroeconomic environment has adversely impacted Neogen&#39;s financial operations. Governments and insurance companies continue to look for ways to contain the rising cost of healthcare. This might put pressure on players in the healthcare industry, with Neogen being no exception.&nbsp; Although the company is gradually coming out of the impact of the two-and-a-half-year-long pandemic, deteriorating international trade, with global inflationary pressure leading to a tough situation related to raw material and labor cost as well as freight charges, and a higher interest rate have put the medical device space in a tight spot.
With sustained macroeconomic pressure, the company may struggle to keep its cost of revenues and operating expenses in check. In fiscal 2024, sales and marketing expenses rose 29.5% year over year. Our model forecasts a 1.5% rise in the metric for fiscal 2025.
Further, Neogen faces intense competition from companies ranging from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, Neogen has faced intense competition resulting from the development of new technologies by the company&#39;s competitors, which could affect the marketability and profitability of Neogen&#39;s products.
<h2>Factors That May Offset the Risks for NEOG Stock</h2>
Neogen is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets. In the fiscal fourth quarter, the Indicator Testing, Culture Media &amp; Other product categories benefited from double-digit growth in the Petrifilm product line as well as solid growth in culture media and food quality nutritional analysis. Additionally, the Vet Instruments and Disposables product line witnessed solid core growth. In the Animal care and other product category, core growth was led by higher sales of vitamin injectables and Biologics products.
<div class="chart_embed">
<h2>Neogen Corporation Price</h2>
<img alt="Neogen Corporation Price" src="https://staticx-tuner.zacks.com/images/charts/a6/1724841357.png" style="height:251px; width:538px" title="" />
Neogen Corporation price | Neogen Corporation Quote
Neogen also continues to carry out its strong R&amp;D activities. During the fiscal fourth quarter, Neogen&#39;s R&amp;D expenses totaled $5.1 million, up sequentially 4.1%.
</div>
The company is expanding well in other geographies. The company is seeing double-digit sales growth in Latin America, with strong performance across most key product categories.&nbsp; The business in Europe and Asia Pacific grew in low single digits and mid-single digits, respectively, with strength in Culture media, Petrifilm, General Sanitation and Sample Handling.
<h2>Key Picks</h2>
Some better-ranked stocks in the broader medical space are Intuitive Surgical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), TransMedics Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and Boston Scientific (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>). While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Boston Scientific currently carries a Zacks Rank of 2 (Buy).
Intuitive Surgical&#39;s shares have surged 55.4% in the past year. Estimates for the company&#39;s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.
ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.
Estimates for TransMedics&#39; 2024 earnings per share have moved up 48.1% to $1.20 in the past 30 days. Shares of the company have risen 174.1% in the past year compared with the industry&#39;s 9.2% growth.
TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 46% compared with the industry&#39;s 9.2% growth.
In the last reported quarter, BSX delivered an earnings surprise of 6.90%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.
<a href="https://www.zacks.com/stock/news/2328483/neogen-suffers-from-competitive-pressure-macroeconomic-woes?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2328483">To read this article on Zacks.com click here.</a>

Large Cap

Macro Economic Events

Mid Cap

Economics

Markets

Trading Ideas

ISRG

TMDX

Neogen Suffers From Competitive Pressure, Macroeconomic Woes

Piper Sandler analyst David Westenberg maintains Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with a Neutral and raises the price target from $17 to $17.5.

Piper Sandler Maintains Neutral on Neogen, Raises Price Target to $17.5

Neogen shares are trading higher after the company reported better-than-expected Q4 revenue results.

Health Care

Neogen Expects FY2025 Adjusted EBITDA Of $215M-$235M, While Capital Expenditures Are Expected To Be Approximately $85M, Including Approximately $55M Related Specifically To The Integration Of The Former 3M Food Safety Division

Neogen Initiates Its Full-year Outlook For Fiscal Year 2025, With Revenue Guidance Of $925M-$955M Versus Consensus Of $938.743M

Neogen Q4 2024 Adj. EPS $0.10 Misses $0.12 Estimate, Sales $236.794M Beat $225.837M Estimate

Neogen Corporation&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neog#NASDAQ">NEOG</a>) effectively progresses with its strategic growth pillars, placing the company well for future success. The Animal Safety segment thrives from the successful consumables product line and also boasts a promising future in genomic services. Additionally, the company&#39;s slew of impressive product introductions nicely sets up for growth in the upcoming quarters.
Meanwhile, the adverse macroeconomic pressure on operations and competitive disadvantages remain our concerns for Neogen&#39;s operations.
In the past year, this Zacks Rank #3 (Hold) stock has declined 28.3% compared with a 2.4% fall of the industry&nbsp;and a 26.6% increase in the S&amp;P 500.
The renowned food and animal safety product provider has a market capitalization of $3.29 billion. The company has an earnings yield of 3.7% compared with the industry&#39;s 1% yield. However, in the trailing four quarters, NEOG delivered an average negative earnings surprise of 5.6%.
Let&#39;s delve deeper.
<h3>Factors at Play</h3>
Progress in Long-Term Growth Strategy:&nbsp;Neogen focuses on boosting the sales of existing products, launching new products, expanding overseas and forming strategic alliances. The company is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets. Their R&amp;D activities have been strong, having expensed $4.9 million in the fiscal third quarter.
Internationally, Neogen is witnessing improvements in sales across Europe, Latin America, Japan and China, banking on strong growth in Petrifilm, pathogens, sample handling and genomics. The company has advanced its food safety data analytics strategy by acquiring Corvium, the SaaS provider behind its software analytics platform.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/8e/70369.jpg?v=853620461" />
Image Source: Zacks Investment Research
The integration of the 3M Food Safety Division is on track, with the company completing the relocation of the former 3M pathogen detection product line and starting production in one of the Lansing facilities. Also, the final relocation of the sample handling production is expected to be completed by the end of the fiscal year, with production likely to begin in the fiscal 2025 first quarter.
Bright Prospects of Animal Safety:&nbsp;Neogen&#39;s Animal Safety segment is gaining from the strong performances of a complete line of consumable products marketed to veterinarians and animal health product distributors. Further, its genomic identification and related interpretive bioinformatics services, too, are showing strong prospects.
The business continues to grow, led by sales of vet instruments and disposables and a new line of business with a large retail customer. Within the biosecurity portfolio, Neogen continues to grow solidly in cleaners, disinfectants and rodenticides. In the fiscal third quarter, revenues in the Animal Safety segment were $71.1 million, up 6.5% year over year. Following a period of a choppy scenario in terms of inventory level destocking, Animal Safety has started to witness a favorable trend.
Product Launches:&nbsp;The launch of the Molecular Detection Assay 2 &ndash; Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST) kit is highly relevant for the poultry industry, expanding Neogen&#39;s pathogen detection assay offering. The company also launched Farm Fluid MAX in Great Britain, which is a dual-action disinfectant designed for challenging farm conditions. The new Veratox VIP assay for the detection of walnuts marks the third assay in Neogen&#39;s Veratox VIP line of enhanced quantitative ELISA products.
In January 2024, the company furthered its innovations with SureKill Gel Bait Pro Applicator, which allows users to easily target inconvenient and challenging areas while minimizing bait waste and innovating baiting protocols. Last year, Neogen launched Igenity Enhanced Dairy, a new and progressive genomic data management tool and debuted new genetic tests through Paw Print Genetics and Canine HealthCheck solutions.
<h3>Downsides</h3>
Global Economic Problems Dent Growth: The company&#39;s international business continues to be affected by currency movements. Governments and insurance companies are looking for ways to curb the rising cost of healthcare, potentially affecting healthcare industry players like Neogen. Furthermore, macroeconomic pressures such as deteriorating international trade, rising inflation, increased raw material, labor and freight costs, as well as higher interest rates, are posing challenges for the company in managing its cost of revenues and operating expenses.
Competitive Landscape Tough: Neogen faces intense competition from both small businesses to large multinational organizations with substantially greater financial resources. Historically, the development of new technologies by competitors has affected the marketability and profitability of the company&#39;s products.
<h3>Estimate Trend</h3>
In the past 30 days, the Zacks Consensus Estimate for Neogen&#39;s earnings for fiscal 2024 has remained constant at 46 cents.
The Zacks Consensus Estimate for the company&#39;s fiscal 2024 revenues is pegged at $912.7 million, which suggests a 10.9% rise from the fiscal 2023 reported number.
<h3>Key Picks</h3>
Some better-ranked stocks in the broader medical space are Hims &amp; Hers Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>), Medpace (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/medp#NASDAQ">MEDP</a>) and ResMed (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>).
Hims &amp; Hers Health&#39;s earnings are expected to surge 281.8% in 2024 compared with the industry&#39;s 15.7%. HIMS&#39; earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. Its shares have surged 136.9% against the industry&#39;s 25.2% decline in the past year.
HIMS sports a Zacks Rank #1 (Strong Buy) at present.
Medpace, carrying a Zacks Rank #2 (Buy) at present, has an estimated 2024 earnings growth rate of 27.1% compared with the industry&#39;s 13.1%. Shares of MEDP have rallied 72.3% compared with the industry&#39;s 5.7% growth over the past year.
MEDP&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.
ResMed, also carrying a Zacks Rank #2 at present, has an estimated fiscal 2024 earnings growth rate of 19.6% compared with the industry&#39;s 12.9%. Shares of RMD have dropped 11.9% compared with the industry&#39;s 2.5% decline over the past year.
RMD&#39;s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 2.8%. In the last reported quarter, it delivered an earnings surprise of 10.9%.
<a href="https://www.zacks.com/stock/news/2297180/here-s-why-staying-invested-in-neogen-neog-could-be-beneficial?cid=CS-BENZ-FT-analyst_blog|rank_focused-2297180">To read this article on Zacks.com click here.</a>

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MEDP

Here's Why Staying Invested in Neogen Could be Beneficial

Investors looking to dial up their risk-reward profile typically consider targeting small publicly traded enterprises that offer robust upside potential. Of course, the main threat to this  framework is volatility. While that risk can never be completely mitigated, the AlphaMark Actively Managed Small Cap ETF (SMCP) provides market speculators with a more sensible platform.  
Fundamentally, the SMCP exchange-traded fund offers two core advantages. Firstly, AlphaMark is actively managed, which means that the investment vehicle is guided by a professional. As market conditions change, the SMCP may navigate around certain pitfalls. Secondly, the ETF&nbsp; encompasses a wide range of individual enterprises. Therefore, no one company will completely sink the portfolio.&nbsp;&nbsp;
Generally, small-capitalization firms have not always performed well. One of the headwinds impacting the ecosystem have been elevated benchmark interest rates. According to Reuters1, small caps started surging in late 2023 – as reflected by the rising per-unit price of SMCP – due to speculation of incoming rate cuts. However, the acceleration eventually faded as inflationary pressures stubbornly stood their ground.  
Nevertheless, some relief in this department could possibly be on the way. Based on the latest information 2 from the Labor Department, while the number of new applicants for jobless claims decreased from the prior week, the total number of people requesting some form of government assistance increased. This dynamic suggests that the <a href="https://www.benzinga.com/news/large-cap/24/06/39225961/job-market-booms-in-may-payrolls-surge-more-than-expected-wages-increase">red-hot labor market</a> is beginning to cool.&nbsp;&nbsp;
Naturally, the framework presents a possible incentivization for the Federal Reserve to present&nbsp; a more accommodative or dovish shift in monetary policy. If so, that could potentially reignite&nbsp; sentiment in small-cap entities, which may have a positive effect on SMCP.&nbsp;&nbsp;
Presently, the top holding of the fund is Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>), an omnichannel retailer of popular apparel brands. ANF represents 1.48% of the small-cap fund.&nbsp; Coming in second place is Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>), an enterprise in the electronic components segment that provides optical packaging and precision manufacturing services. It carries a fund weighting of 1.38%.&nbsp;&nbsp;
Rounding out the top three is Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>), which falls under the diagnostics and research sector of the healthcare ecosystem. It focuses on products and services dedicated to food and animal safety and features 1.31% of the SMCP ETF. Visit&nbsp; <a href="https://alphamarkadvisors.com/etf/" title="https://alphamarkadvisors.com/etf/">https://alphamarkadvisors.com/etf/</a> to obtain Top 10 holdings of SMCP ETF.&nbsp;&nbsp;
To be sure, <a href="https://www.benzinga.com/news/small-cap">small-cap stocks</a> present a higher-risk profile than that of mid or especially large cap firms. Primarily, small caps simply require <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38648713/as-large-cap-stocks-take-a-breather-and-the-spy-trades-sideways-will-small-cap-stocks-st">more due diligence</a>. Part of the reason is that because the underlying businesses tend to be relatively diminutive, not many analysts cover the space. As a result, there are likely to be informational gaps. These gaps can catch unprepared investors off guard yet this unpredictability also facilitates opportunities for upside.&nbsp;&nbsp;
The SMCP Chart: Since its public market debut in 2015, the SMCP ETF has returned 20%.&nbsp; Perhaps not surprisingly, the fund tends to be choppy, with some of the strongest players lifting the portfolio while downside performances in the least-promising names have caused snap volatility.&nbsp;&nbsp;
• Over the past 52 weeks, the SMCP is up around 20% based on closing prices. Since&nbsp; approximately early March, however, the ETF has entered into a sideways trend&nbsp; channel. That might present an entry point for prospective investors, especially as the&nbsp; market appears to be looking for its next big catalyst.&nbsp;&nbsp;
• At the moment, SMCP trades hands at $30.60. That's modestly above its 50-day moving average, which comes in at $30.49. However, the fund is also a hair below its 20 DMA&nbsp; (Displaced Moving Average), which stands at $30.77. Notably, an upside resistance line has materialized at the $31 level. That would be the next logical target for the fund to cross.&nbsp;&nbsp;
• A support line has been established at the $30 level. That's also a psychologically satisfying whole number that the bulls need to maintain. Bearish traders will attempt to drive down the price below this key threshold, which could trigger automated sell orders.&nbsp;&nbsp;
• A big acquisition volume spike that flashed on the June 17 session will offer encouragement to the optimists, especially as they wait for news that could benefit small caps, such as an accommodative (dovish) monetary policy.  
<figure class="wp-block-image"><img decoding="async" src="https://lh7-us.googleusercontent.com/docsz/AD_4nXecNj2ySyR9OY8nE-E0rQkqX6HOTWFlidoLyvC7TA52FezZkqMhk1OYFiWyq7CFOmlLBQtIkL69-8djpzYcAxjF7z9vwifJFQ_9-D5grIDlJRh6DIjTr_wQ_PSJ6ACUysnjorirPENq3FyjWjJZYDLp7DsZ?key=wALxegg3tHTHHTWasx9j7w" alt="" /></figure>
Past performance is not a guarantee of future results. The investment return and the principal value of an investment in the Fund will fluctuate so that an investor's shares,&nbsp; when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data cited. Current month-end data is available at 859-957-1803.&nbsp;&nbsp;
Visit <a href="https://alphamarkadvisors.com/etf/">https://alphamarkadvisors.com/etf/</a>&nbsp; for more information about the AlphaMark Actively&nbsp; Managed Small Cap ETF. Standardized fund performance can also be found through the link in&nbsp; addition to more information.&nbsp;&nbsp;
Featured photo by StockSnap from Pixabay &nbsp;
The fund's investment objectives, risks, charges and expenses must be considered carefully before investing. The prospectus and summary prospectus contains this and other important information about the investment company, or a free, hard-copy may be obtained by calling&nbsp; 1-800-730-3457. Read it carefully before investing. Investing involves risk. Principal loss is possible. Investing involves risk. Principal loss is possible. When the Fund invests in ADRs as a substitute for an investment directly in the Underlying Shares, the Fund is exposed to the risk that the ADRs may not provide a return that corresponds precisely with that of the&nbsp; Underlying Shares. The Fund is non-diversified, meaning it may concentrate its assets in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual stock volatility than a diversified fund. A Fund that concentrates its investments in the securities of a particular sector area may be more volatile than a fund that invests in a broader range of industries.
The Fund invests in foreign securities which involve political, economic and currency risks,&nbsp; greater volatility and differences in accounting methods. These risks are greater for investments i n emerging markets. The Fund invests in smaller companies, which involve additional risks such as limited liquidity and greater volatility. REITs may have limited financial resources, may trade less frequently and in limited volume, and may be more volatile than other securities. Investing in investment companies, such as ETFs will subject the Fund to additional expenses of each investment company and risk of owning the underlying securities held by each. ETFs may trade at a premium or discount to their net asset value. ETFs are bought and sold at market price and not individually redeemed from the fund. Brokerage commissions will reduce returns. Fund holdings and sector allocations are subject to change at any time and should not be considered recommendations to buy or sell any security. The SEC does not endorse, indemnify,&nbsp; approve, nor disapprove of any security.&nbsp;&nbsp;
AlphaMark Advisors LLC is the Advisor to the AlphaMark Actively Managed Small Cap ETF&nbsp; which is distributed by Quasar Distributors, LLC.&nbsp;&nbsp;
Footnotes:&nbsp;&nbsp;
1 <a href="https://www.reuters.com/markets/us/wall-st-week-ahead-us-small-caps-struggle-elevated-interest-rat">https://www.reuters.com/markets/us/wall-st-week-ahead-us-small-caps-struggle-elevated-interest-rat&nbsp; es-take-toll-2024-05-03/</a> &nbsp;
2 <a href="https://www.reuters.com/markets/us/us-weekly-jobless-claims-fell-latest-week-2024-06-20/">https://www.reuters.com/markets/us/us-weekly-jobless-claims-fell-latest-week-2024-06-20/</a>&nbsp;

Long Ideas

Short Ideas

Technicals

ETFs

Inflation Slows Small Cap Rally, But SMCP ETF Offers Strategic Entry Point

Neogen Q2 2025 Earnings Preview

Here's the major earnings before the open tomorrow

Neogen Non-GAAP EPS of $0.11 beats by $0.01, revenue of $231.3M beats by $3.23M

Sees Q2 revenue $231.3M, consensus $228.07M. "The second quarter reflected steady progress, as we saw improvement across the business compared to t...

Neogen sees Q2 adjusted EPS 11c, consensus 10c

Neogen Corporation (NEOG) Q2 2025 Earnings Call Transcript

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Disney (DIS), Fox (FOXA), and Warner B...

Venu Sports JV discontinued, Walgreens reports Q1 beat: Morning Buzz

Neogen ( ($NEOG) ) has released its Q2 earnings. Here is a breakdown of the information Neogen presented to its investors. Neogen Corporation speci...

Neogen Corporation Reports Q2 2025 Earnings Highlights

Neogen: Food Safety Play Is Far From A Safe Pay

Neogen (NEOG) launched the new Neogen Molecular Detection Assay 2 – Quantitative Salmonella. The Neogen MDA2QSAL96 kit integrates qualitative patho...

Neogen launches salmonella molecular detection assay

Neogen launches new MDA2 quantitative salmonella molecular detection assay

ACHR

ARHS

ATRO

AVDL

BCRX

FOXA

GBTG

GOOG

GOOGL

ITCI

JOBY

MVST

SDZNY

SDZXF

SPOT

SVNDF

SVNDY

Press Releases

Neogen Announces the Appointment of New Board Member

Neogen Announces First-Quarter 2025 Results

Neogen® To Participate in 2024 UBS Global Healthcare Conference

Neogen® to Participate in the 36th Annual Piper Sandler Healthcare Conference

Neogen® Launches Petrifilm® Bacillus cereus Count Plate to Enhance Food Safety Testing Efficiency

Neogen® Announces Second-Quarter Earnings Release Date

Neogen® Announces Change to Second-Quarter Earnings Release Date

Neogen® To Participate in Upcoming Investor Conferences

Neogen Announces Preliminary¹ Second-Quarter 2025 Results

Neogen® Launches New MDA2 Quantitative Salmonella Molecular Detection Assay

QGEN

Align Tech

Avanos Medical

Bioventus

Cerus

The Cooper Companies, Inc. - Common Stock

Cooper Companies

Embecta

Establishment Labs Holdings Inc. - Common Shares

Establishment Labs Hldgs

Haemonetics

ICU Medical

OrthoPediatrics

Lantheus Holdings

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems

InspireMD

OraSure Technologies, Inc. - Common Stock

OraSure Technologies

Rockwell Medical

RxSight

Sanara MedTech

Solventum

Staar Surgical

TELA Bio

UFP Techs

Utah Medical Products, Inc. - Common Stock

Utah Medical Products

WORK Medical Technology Group LTD - Ordinary Shares

WORK Medical Technology

Dentsply Sirona

Xtant Medical Holdings, Inc. Common Stock

Xtant Medical Hldgs

Guggenheim

Piper Sandler

Wells Fargo

Neogen Corporation

これらの中型株は直近1週間で最も好調のパフォーマンスを示しました。あなたのポートフォリオには入っていますか？
<ol>
<li>Agios Pharmaceuticals Inc(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>)株は、企業が依存性輸血（TD）アルファまたはベータ地中海貧血の患者を対象にした臨床試験で<a href="https://www.benzinga.com//node/39141375">主要エンドポイントを達成</a>したと発表した後、先週29.13％急騰しました。 この発表を受けて、数人のアナリストが予測を<a href="https://www.benzinga.com/quote/agio/analyst-ratings">引き上げました</a>。</li>
<li>Verint Systems Inc。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>）の株価は、同社が先週火曜日に<a class="ticker" href="https://www.benzinga.com//node/39170267" target="_blank" rel="noreferrer noopener">予想を上回るQ1業績を発表し、強いFY25業績予測を示した</a>ことを受けて22.40％上昇しました。</li>
<li>Novavax Inc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>）の株は先週、米国食品医薬品局（FDA）の諮問委員会が新型コロナウイルスのJN.1系統向けの<a href="https://www.benzinga.com/general/biotech/24/06/39204978/novavax-stock-rallies-in-pre-market-as-company-plans-to-deliver-covid-19-vaccine-by-september">更新されたワクチンの推奨を可決した</a>と発表した後、21.54％上昇しました。</li>
<li>Nuvalent, Inc。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>）の株は20.52％上昇しました。</li>
<li>Neogen Corporation（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>）の株は19.25％上昇しました。</li>
<li>Twist Bioscience Corporation（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>）の株価は、Guggenheimが<a class="ticker" href="https://www.benzinga.com/quote/twst/analyst-ratings" target="_blank" rel="noreferrer noopener">株を「Buy」のレーティングでカバーし、53ドルの</a><a href="https://www.benzinga.com//node/39206468" target="_blank" rel="noreferrer noopener">株価ターゲットを発表した</a><a class="ticker" href="https://www.benzinga.com/quote/twst/analyst-ratings" target="_blank" rel="noreferrer noopener">ことで18.40％急騰しました。</a></li>
<li>Smartsheet Inc。（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>）の株価は、同社が予想を上回るQ1業績を発表し、<a href="https://www.benzinga.com//node/39195040" target="_blank" rel="noreferrer noopener">初めての1億5000万ドルの株買い戻しプログラムを発表した</a>ことで18.01％上昇しました。 これを受け、多くのアナリストが<a href="https://www.benzinga.com//node/39206468" target="_blank" rel="noreferrer noopener">株価ターゲットを変更しました</a>。</li>
<li>Halozyme Therapeutics, Inc。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>）の株価は14.03％急伸し、同社が<a href="https://www.benzinga.com//node/39211537" target="_blank" rel="noreferrer noopener">FY24業績見通しを引き上げた</a>ことが要因です。</li>
<li>Legend Biotech Corporation（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>）の<a href="https://www.benzinga.com/quote/legn/analyst-ratings" target="_blank" rel="noreferrer noopener">株価が13.93％上昇しました</a>。</li>
<li>Liberty Global Ltd。（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYB#NASDAQ">LBTYB</a>）の株価は12.48％上昇しました。</li>
</ol>

Comments

Neogen

ニュース

最新ニュース Neogen (NASDAQ:NEOG) 株価情報

月曜日, 6 10, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル